{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:48:40Z","timestamp":1792759720295,"version":"4.5.0"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>After the COVID-19 pandemic, many patients have reported chronic fatigue and\n                    severe post-exertional malaise, with symptoms similar to those of myalgic\n                    encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). The accumulation of\n                    agonistic receptor autoantibodies targeting beta-adrenergic (\u03b21 and \u03b22) and\n                    muscarinic (M3 and M4) neurotransmitter receptors may play a crucial role in the\n                    pathomechanism of both ME\/CFS and post-COVID conditions. Therapeutic apheresis\n                    has been suggested as an effective treatment option for alleviating and\n                    mitigating symptoms in this desperate group of patients. In this single-center\n                    pilot study, we analyzed autoantibodies in a cohort of 20 post-COVID patients\n                    before and after therapeutic apheresis. Apheresis resulted in a decline of \u03b21 or\n                    \u03b22 adrenergic receptor antibodies in all patients. Additionally, the majority of\n                    patients experienced a concurrent reduction in symptoms such as fatigue,\n                    physical activity restrictions, myalgia, post-exertional malaise, and\n                    concentration disorders. This study clearly demonstrates an association between\n                    autoantibodies and the clinical improvement of post-COVID patients. Even if\n                    future sham-controlled trials do not show a positive outcome, extracorporeal\n                    apheresis may still be valuable for this patient group by temporarily improving\n                    microperfusion and symptoms. Success in restoring patients to work and normal\n                    life, as observed in many individuals after therapeutic apheresis, should be\n                    recognized. Therefore, we believe that extracorporeal therapeutic apheresis, as\n                    part of a multimodal treatment, should be considered an early intervention for\n                    postinfectious syndromes in selected patients.<\/jats:p>","DOI":"10.1055\/a-2445-8593","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T18:32:47Z","timestamp":1733769167000},"page":"869-874","source":"Crossref","is-referenced-by-count":8,"title":["A Single-Center Pilot Study of Therapeutic Apheresis in Patients with\n                    Severe Post-COVID Syndrome"],"prefix":"10.1055","volume":"56","author":[{"given":"Johannes","family":"Korth","sequence":"additional","affiliation":[{"name":"Apherese-Zentrum am Kortumpark, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-4860","authenticated-orcid":false,"given":"Charlotte","family":"Steenblock","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital Carl Gustav Carus,\n                    Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Walther","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital Carl Gustav Carus,\n                    Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Barbir","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital Carl Gustav Carus,\n                    Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"Department of Cardiology, Harefield Hospital, Royal Brompton and\n                    Harefield NHS Foundation Trust Hospital, Harefield, United Kingdom of Great\n                    Britain and Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Husung","sequence":"additional","affiliation":[{"name":"MedSelect GmbH, L\u00fcdenscheid, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Velthof","sequence":"additional","affiliation":[{"name":"Apherese-Zentrum am Kortumpark, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12967-024-05349-7","article-title":"Systematic review of fatigue severity in ME\/CFS patients: insights from\n                    randomized controlled trials","volume":"22","author":"J W Park","year":"2024","journal-title":"J Transl Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e0193672","DOI":"10.1371\/journal.pone.0193672","article-title":"Immunoadsorption to remove ss2 adrenergic receptor antibodies in Chronic Fatigue\n                    Syndrome CFS\/ME","volume":"13","author":"C Scheibenbogen","year":"2018","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41380-021-01148-4","article-title":"Chronic post-COVID-19 syndrome and chronic fatigue syndrome: is there a role for\n                    extracorporeal apheresis?","volume":"27","author":"S R Bornstein","year":"2022","journal-title":"Mol Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"103445","DOI":"10.1016\/j.autrev.2023.103445","article-title":"Severity of neurological Long-COVID symptoms correlates with increased level of\n                    autoantibodies targeting vasoregulatory and autonomic nervous system\n                    receptors","volume":"22","author":"F S Seibert","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.61373\/bm024p.0064","article-title":"A multimodal approach for treating post-acute infectious syndrome","volume":"1","author":"C Steenblock","year":"2024","journal-title":"Brain Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","article-title":"Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long\n                    COVID: a meta-analysis and systematic review","volume":"226","author":"C Chen","year":"2022","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1055\/a-1945-9694","article-title":"Post COVID and apheresis \u2013 where are we standing?","volume":"54","author":"C Steenblock","year":"2022","journal-title":"Horm Metab Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and\n                    their impact","volume":"38","author":"H E Davis","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbi.2015.09.013","article-title":"Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients\n                    with chronic fatigue syndrome","volume":"52","author":"M Loebel","year":"2016","journal-title":"Brain Behav Immun"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.autrev.2018.01.009","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome \u2013 evidence for an autoimmune\n                    disease","volume":"17","author":"F Sotzny","year":"2018","journal-title":"Autoimmun Rev"},{"key":"ref11","first-page":"428","article-title":"Risk factors associated with long COVID syndrome: a retrospective study","volume":"46","author":"A A Asadi-Pooya","year":"2021","journal-title":"Iran J Med Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.transci.2017.08.010","article-title":"Selective plasma exchange","volume":"56","author":"A Ohkubo","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e0129898","DOI":"10.1371\/journal.pone.0129898","article-title":"B-Lymphocyte depletion in myalgic encephalopathy\/chronic fatigue syndrome. An\n                    open-label phase II study with rituximab maintenance treatment","volume":"10","author":"\u00d8 Fluge","year":"2015","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2796.2011.02428.x","article-title":"Myalgic encephalomyelitis: International Consensus Criteria","volume":"270","author":"B M Carruthers","year":"2011","journal-title":"J Intern Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1038\/s41380-023-02084-1","article-title":"Clinical improvement of long-COVID is associated with reduction in\n                    autoantibodies, lipids, and inflammation following therapeutic apheresis","volume":"28","author":"M Achleitner","year":"2023","journal-title":"Mol Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/1744-9987.13974","article-title":"Immunoadsorption to treat patients with severe post-COVID syndrome","volume":"27","author":"B Giszas","year":"2023","journal-title":"Ther Apher Dial"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/jcm9082443","article-title":"Myalgic encephalomyelitis\/chronic fatigue syndrome: efficacy of repeat\n                    immunoadsorption","volume":"9","author":"M Tolle","year":"2020","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.3390\/jcm12196428","article-title":"Observational study of repeat Immunoadsorption (RIA) in post-COVID ME\/CFS\n                    patients with elevated ss2-adrenergic receptor autoantibodies \u2013 an interim\n                    report","volume":"12","author":"E Stein","year":"2023","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1085988","DOI":"10.3389\/fmed.2023.1085988","article-title":"Biomarkers in long COVID-19: a systematic review","volume":"10","author":"Y J Lai","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"10458","DOI":"10.3390\/ijms241310458","article-title":"Laboratory findings and biomarkers in long COVID: what do we know so far?\n                    Insights into epidemiology, pathogenesis, therapeutic perspectives and\n                    challenges","volume":"24","author":"D Tsilingiris","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40249-023-01086-z","article-title":"Increased interleukin-6 is associated with long COVID-19: a systematic review\n                    and meta-analysis","volume":"12","author":"J X Yin","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2133.2003.05233.x","article-title":"Successful treatment by double-filtration plasmapheresis of a patient with\n                    bullous pemphigoid: effects in vivo on transcripts of several genes for\n                    chemokines and cytokines in peripheral blood mononuclear cells","volume":"148","author":"Y Hatano","year":"2003","journal-title":"Br J Dermatol"},{"key":"ref24","first-page":"17","article-title":"Bridging the gap. The separate worlds of evidence-based medicine and\n                    patient-centered medicine","volume":"39","author":"J Bensing","year":"2000","journal-title":"Patient Educ Couns"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2445-8593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T19:00:42Z","timestamp":1737572442000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2445-8593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2445-8593","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}